Systemic reaction to pneumococcal vaccine: How common in pediatrics?

Allergy and Asthma Proceedings

Volumn 29, Issue 4, 2008, Pages 397-399

  Yousef, Ejaz ^a   Mannan, Susan ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Adverse reaction; Antibody; Immunization; Immunodeficiency; Pneumococcus; Pneumovax; Polysaccharide; Prevnar; Titer; Vaccine

Indexed keywords

23 VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; BACTERIUM ANTIBODY; PNEUMOCOCCUS VACCINE;

ARTICLE; BLOOD; CASE REPORT; CELLULITIS; CHEMICALLY INDUCED DISORDER; CHILD; DIARRHEA; EDEMA; ERYTHEMA; FEVER; HUMAN; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOLOGY; MALE; PAIN; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; VOMITING;

ANTIBODIES, BACTERIAL; CELLULITIS; CHILD; CHILD, PRESCHOOL; DIARRHEA; EDEMA; ERYTHEMA; FEVER; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOCOMPROMISED HOST; MALE; PAIN; PNEUMOCOCCAL VACCINES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; VOMITING;

EID: 50249099793     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2008.29.3144     Document Type: Article

References (11)

1. Moylett EH, and Hanson IC. Mechanistic actions of the risks and adverse events associated with vaccine administration. J Allergy Clin Immunol 114:1010-1020, 2004.
2. Centers for Disease Control and Prevention. Preventing Pneumococcal disease among infants: Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 49:1-38, 2000.
3. Centers for Disease Control and Prevention. Health objectives for the nation. Public health burden of vaccine-preventable diseases among adults: Standards for adult immunization practice. MMWR Morb Mortal Wkly Rep 39:725-729, 2000.
4. Centers for Disease Control and Prevention. Recommendations of the Immunization Practices Advisory Committee: Pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 38:64-68, 73-76, 1989.
5. Rodriguez R, and Dyer PD. Safety of pneumococcal revaccination. J Gen Intern Med 10:511-512, 1995.
6. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 281:243-248, 1999.
7. Ponka A, and Leinonen M. Adverse reactions to polyvalent pneumococcal vaccine. Scand J Infect Dis 14:67-71, 1982.
8. Hasan S, Yousef M, and Shridharani S. Severe febrile systemic reaction to pneumococcal vaccine. J Natl Med Assoc 97:284-285, 2005.
9. Holdiness MR. Rare systemic dermatologic reaction after pneumococcal vaccine administration. South Med J 96:64-65, 2003.
10. Gherardi RK, and Authier FJ. Aluminum inclusion macrophagic myofasciitis: A recently identified condition. Immunol Allergy Clin North Am 23:699-712, 2003.
11. Rimaniol AC, Gras G, Verdier F, et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 22:3127-3135, 2004.